Vanoxerine National Institute on Drug Abuse.

@article{Preti2000VanoxerineNI,
  title={Vanoxerine National Institute on Drug Abuse.},
  author={Antonio Preti},
  journal={Current opinion in investigational drugs},
  year={2000},
  volume={1 2},
  pages={241-51}
}
  • Antonio Preti
  • Published 2000 in Current opinion in investigational drugs
Vanoxerine (GBR-12909) is a high-affinity dopamine reuptake inhibitor that was synthesized in the late 1970s and was initially tested in Europe as a potential antidepressant. In 1989, it was suggested that GBR-12909 might be useful in the treatment of cocaine addiction [346980]. The drug has completed phase I clinical trials conducted by the US National Institute on Drug Abuse for the potential treatment of cocaine abuse [346245,376621]. A multidose, safety and pharmacokinetics, open-label… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Vanoxerine ( GBR-12909 ) is a high - affinity dopamine reuptake inhibitor that was synthesized in the late 1970s and was initially tested in Europe as a potential antidepressant .
The drug has completed phase I clinical trials conducted by the US National Institute on Drug Abuse for the potential treatment of cocaine abuse [ 346245,376621 ] .
Vanoxerine ( GBR-12909 ) is a high - affinity dopamine reuptake inhibitor that was synthesized in the late 1970s and was initially tested in Europe as a potential antidepressant .
All Topics